Type 1 Diabetes
The Immunobiology Lab at MGH is currently conducting multiple clinical trials using Bacillus Calmette-Guérin (BCG), an inexpensive generic drug, as a treatment for advanced type 1 diabetes. The BCG clinical trial program has been underway for almost 10 years. To date, more than 230 patients with longstanding type 1 diabetes have been enrolled in BCG clinical trials. A 150-patient, randomized, placebo-controlled, Phase II clinical trial is currently fully enrolled and all patients have been followed for at least one year. Other clinical studies include those related to ongoing biomarker development, BCG strain comparison, drug stability with different BCG formulation formats and systemic glucose utilization. In March 2022 MGH announced the launch of a multicenter pediatric trial in collaboration with NYU Langone Medical Center. The pediatric trial is actively enrolling type 1 diabetic children aged 12 to 17.
If you would like to be considered for participation in our clinical trials, please fill out the Registration Form found at this link: https://redcap.link/faustmanimmunobiologylab. This will enter your information into our clinical trial database. We use this database to screen and select patients for future studies. In addition, we will add you to our mailing list so that you can receive our newsletters and updates
The Immunobiology Lab at MGH is currently participating in a clinical trial using Bacillus Calmette-Guérin (BCG) to prevent complications from COVID-19. More information about enrollment will be available. soon.